Disruption of PPAR-γ signaling impairs adipose tissue function, promoting IR, lipid metabolism dysregulation, and fibrosis, thus accelerating both MASLD and CKD progression [4,117,118,119]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.